Clinical-stage biopharmaceutical company Nuvalent, Inc. (Nasdaq:NUVL) announced on Monday the initiation of HEROEX-1, a Phase 1a/1b clinical trial for NVL-330.
NVL-330 is a novel HER2-selective inhibitor targeting HER2-altered non-small cell lung cancer (NSCLC) in pre-treated patients. HER2 alterations, including exon 20 mutations, are key oncogenic drivers in NSCLC with no approved TKIs for this patient population. NVL-330 aims to address this by maintaining activity against HER2 exon 20 mutations, limiting EGFR-related toxicities, and penetrating the brain to tackle metastases.
HEROEX-1 will evaluate NVL-330's safety, tolerability, recommended Phase 2 dose, pharmacokinetic profile and preliminary anti-tumor activity.
This trial involves a multicenter, open-label, dose-escalation and expansion study design. NVL-330's differentiated preclinical profile supports its potential efficacy in this clinical investigation.
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
hVIVO reports positive results from RSV antiviral human challenge trial
BerGenBio reveals preliminary safety data from Phase 1b BGBC016 study in first-line NSCLC patients
Liquidia and Pharmosa expand collaboration for inhaled treprostinil
Alvotech launches confirmatory study for Entyvio biosimilar
Merck's KEYTRUDA receives new approvals in Japan for lung and urothelial cancers
Innate Pharma receives FDA clearance of IND for IPH4502, a Nectin-4 targeting ADC for solid tumours
Intas Pharmaceuticals reports positive opinion for HETRONIFLY in Europe
Insilico Medicine reveals positive preliminary results from ISM001-055Phase IIa clinical trial
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
AbbVie advances solid tumour pipeline with new data at ESMO 2024
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024